Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 169

Sort by

Sort Order Select

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

CALR mutation burden in essential thrombocythemia and disease outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Alessandro Atanasio, Ilaria Sestini, Audrey Désilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Lambert Busque, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2024) 143 (13): 1310–1314.

https://doi.org/10.1182/blood.2023023428

Published: 2024

Includes: Supplemental data

Journal Articles

Effect of New or Worsening Anemia on Clinical Outcomes in 2233 Patients with Myelofibrosis Treated with Ruxolitinib in the Expanded-Access Jump Study

Vikas Gupta, Paola Guglielmelli, JE Hamer-Maansson, Evan M. Braunstein, Haifa Kathrin Al-Ali

Blood (2023) 142 (Supplement 1): 5174.

https://doi.org/10.1182/blood-2023-179417

Published: 2023

Journal Articles

Combinatorial BCL-2 / BCL2L1 Expression Predicts Clinical Response to Ruxolitinib in Myelofibrosis

Giacomo Coltro, Viola Videschi, Francesca Gesullo, Manjola Balliu, Alessandro M. Vannucchi, Paola Guglielmelli

Blood (2023) 142 (Supplement 1): 1794.

https://doi.org/10.1182/blood-2023-185821

Published: 2023

Journal Articles

The Reticulin, Collagen, Osteosclerosis (RCO) Score Is Clinically and Prognostically Relevant in Patients with Secondary Myelofibrosis (SMF)

Giacomo Coltro, Raffaella Santi, Alessandro Atanasio, Paolo Cicogna, Paola Guglielmelli, Umberto Gianelli, Alessandro M. Vannucchi

Blood (2023) 142 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2023-186288

Published: 2023

Journal Articles

Clinical and Prognostic Validation of the Reticulin, Collagen, Osteosclerosis (RCO) Score for Primary Myelofibrosis (PMF)

Giacomo Coltro, Raffaella Santi, Giuseppe Gaetano Loscocco, Alessandro Atanasio, Paolo Cicogna, Paola Guglielmelli, Umberto Gianelli, Alessandro M. Vannucchi

Blood (2023) 142 (Supplement 1): 1816.

https://doi.org/10.1182/blood-2023-188726

Published: 2023

Journal Articles

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4215.

https://doi.org/10.1182/blood-2023-184845

Published: 2023

Journal Articles

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Andrew Srisuwananukorn, Giuseppe Gaetano Loscocco, Andrew T. Kuykendall, James M Dolezal, Raffaella Santi, Ling Zhang, Avani M Singh, Paola Guglielmelli, Alessandro Maria Vannucchi, Douglas Tremblay, Alexander T Pearson, Mohamed E. Salama, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 901.

https://doi.org/10.1182/blood-2023-173877

Published: 2023

Journal Articles

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Blood (2023) 142 (Supplement 1): 624.

https://doi.org/10.1182/blood-2023-179291

Published: 2023

Journal Articles

Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class

Valentina Boldrini, Paola Guglielmelli, Giada Rotunno, Chiara Maccari, Giacomo Coltro, Giuseppe Gaetano Loscocco, Francesco Mannelli, Naseema Gangat, Ayalew Tefferi, Alessandro M. Vannucchi

Blood (2023) 142 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2023-189571

Published: 2023

Journal Articles

A Population-Based Study on Survival of 652 Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in Italy

Barbara Mora, Giacomo Pellegrini, Matteo Franchi, Olivia Leoni, Daniela D'Ippoliti, Valeria Di Fabrizio, Fabrizio Gemmi, Claudia Szasz, Margherita Maffioli, Carmelo Gurnari, Enrico Attardi, Giovanni Corrao, Paola Guglielmelli, Maria Teresa Voso, Alessandro Maria Vannucchi, Francesco Passamonti

Blood (2023) 142 (Supplement 1): 4572.

https://doi.org/10.1182/blood-2023-182107

Published: 2023

Journal Articles

Chromosome 9p Duplication Promotes T-Cell Exhaustion and Enhances Stem Cell Clonogenic Potential in JAK2-Mutant Myeloproliferative Neoplasms

Blood (2023) 142 (Supplement 1): 1780.

https://doi.org/10.1182/blood-2023-182420

Published: 2023

Journal Articles

Polygenic Germline Risk of Common Haematological Traits Drives Clonal Selection on JAK2 V617F and Development of Myeloproliferative Neoplasms

Jyoti Nangalia, Jing Guo, Klaudia Walter, Pedro Quiros, Muxin Gu, E Joanna Baxter, John Danesh, Emanuele Di Angelantonio, David Roberts, Paola Guglielmelli, Claire N Harrison, Anna L Godfrey, Anthony R Green, George Vassiliou, Dragana Vuckovic, Nicole Soranzo

Blood (2023) 142 (Supplement 1): 863.

https://doi.org/10.1182/blood-2023-189551

Published: 2023

Journal Articles

APL-like Subset within NPM1 -Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

Blood (2023) 142 (Supplement 1): 4224.

https://doi.org/10.1182/blood-2023-173574

Published: 2023

Journal Articles

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Blood (2023) 142 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2023-178599

Published: 2023

Journal Articles

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Lambert Busque, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Alessandro Atanasio, Ilaria Sestini, Audrey Desilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Marie-Christine Meunier, Michael Harnois, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2023) 142 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2023-174076

Published: 2023

Journal Articles

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Blood (2023) 142 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2023-181521

Published: 2023

Journal Articles

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Blood (2022) 140 (Supplement 1): 9688–9690.

https://doi.org/10.1182/blood-2022-157914

Published: 2022

Journal Articles

Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Blood (2022) 140 (Supplement 1): 10622–10623.

https://doi.org/10.1182/blood-2022-162298

Published: 2022

Journal Articles

Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis

Chiara Maccari, Benedetta Sordi, Paola Guglielmelli, Manjola Balliu, Alessandro Atanasio, Carmela Mannarelli, Giulio Capecchi, Ilaria Sestini, Giacomo Coltro, Giada Rotunno, Eva Angori, Filippo C. Borri, Natasha Szuber, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 3955–3956.

https://doi.org/10.1182/blood-2022-156773

Published: 2022

NARROW

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

CALR mutation burden in essential thrombocythemia and disease outcome

Effect of New or Worsening Anemia on Clinical Outcomes in 2233 Patients with Myelofibrosis Treated with Ruxolitinib in the Expanded-Access Jump Study

Combinatorial BCL-2 / BCL2L1 Expression Predicts Clinical Response to Ruxolitinib in Myelofibrosis

The Reticulin, Collagen, Osteosclerosis (RCO) Score Is Clinically and Prognostically Relevant in Patients with Secondary Myelofibrosis (SMF)

Clinical and Prognostic Validation of the Reticulin, Collagen, Osteosclerosis (RCO) Score for Primary Myelofibrosis (PMF)

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class

A Population-Based Study on Survival of 652 Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in Italy

Chromosome 9p Duplication Promotes T-Cell Exhaustion and Enhances Stem Cell Clonogenic Potential in JAK2-Mutant Myeloproliferative Neoplasms

Polygenic Germline Risk of Common Haematological Traits Drives Clonal Selection on JAK2 V617F and Development of Myeloproliferative Neoplasms

APL-like Subset within NPM1 -Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only